| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e27e723c3f05c10ca760291231bacfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f92475a30ee4242881c00b484469a66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-916
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70521 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2002-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b622dd3b6f94f7822e2c3a187cd955b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c39f0529cac5b2aea67dcda333bcf45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c90f19fb0d84ecb323fc500f18930f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92519c9656788a0bbd7b6d30e183e535 |
| publicationDate |
2002-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02066045-A2 |
| titleOfInvention |
Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a |
| abstract |
The present invention provides methods for modulating an immune response comprising contacting a cell with an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention further provides methods for treating a subject having a disorder that would benefit from down regulation of an immune response comprising administering an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention also provides methods for identifying compounds capable of modulating the interaction of CTLA4 and PP2AA. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9052312-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009056633-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009056633-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2008320822-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110234647-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110234647-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105477644-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10041947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9880168-B2 |
| priorityDate |
2001-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |